MicroTransponder Raises $65M to Boost Vivistim Use in Stroke Recovery

MicroTransponder®, Inc., an innovative company based in Austin, Texas, recently raised $65 million in a Series F financing round. This substantial investment reflects the company's commitment to revolutionizing stroke care with its groundbreaking technology, the Vivistim® Paired VNS™ System. The round was significantly supported by US Venture Partners (USVP) and other existing investors such as Osage University Partners, Action Potential Venture Capital, GPG Ventures, The Vertical Group, and Exceller Hunt Ventures. Additionally, Gilde Healthcare and Longitude Capital joined as new investors, underscoring the confidence in MicroTransponder's potential.

Vivistim represents a significant advancement in stroke recovery, as it is currently the sole FDA-approved intervention that has been clinically demonstrated to significantly enhance upper extremity function in chronic ischemic stroke survivors. The device is surgically implanted and works in conjunction with a therapist who administers vagus nerve stimulation (VNS) during repetitive, goal-focused therapeutic exercises. This innovative approach, known as Paired VNS Therapy, leverages the brain's ability to reorganize and form new neural connections, a process called neuroplasticity. As a result, stroke survivors can experience remarkable improvements in the use of their hands and arms, greatly benefiting their daily activities and quality of life.

The recent funding round is expected to further accelerate the development and distribution of the Vivistim System. By expanding access to this transformative technology, MicroTransponder aims to significantly enhance rehabilitation outcomes for stroke patients. The Vivistim device's unique mechanism of action and proven clinical benefits position it as a critical tool in the stroke recovery toolkit, offering hope to countless individuals who face ongoing challenges following a stroke.

The support from a diverse group of investors not only highlights the promise of MicroTransponder's technology but also reflects a broader recognition of the need for innovative solutions in stroke rehabilitation. With this new financial backing, the company is well-equipped to expand its reach and impact, ensuring that more stroke survivors can access the benefits of Paired VNS Therapy.

MicroTransponder's dedication to improving the lives of stroke survivors is evident in its commitment to research, development, and clinical validation. The Vivistim System's ability to enhance neuroplasticity represents a paradigm shift in how therapists approach stroke rehabilitation. By providing a means to regain significant upper limb function, Vivistim empowers individuals to achieve greater independence and improved quality of life.

In summary, the $65 million investment in MicroTransponder underscores the transformative potential of the Vivistim Paired VNS System in stroke care. As the company continues to innovate and expand its offerings, it is poised to make a substantial impact on the lives of stroke survivors, offering new hope and possibilities in the journey to recovery.